@article{nokey,

title = {Physical enhancement of older adults  using hyperbaric oxygen: a randomized  controlled trial},

author = {Amir Hadanny and Efrat Sasson and Laurian Copel and Malka Daniel-Kotovsky and Eldad Yaakobi and Erez Lang and Gregory Fishlev and Nir Polak and Mony Friedman and Keren Doenyas and Shachar Finci and Yonatan Zemel and Yair Bechor and Shai Efrati},

url = {https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-024-05146-3},

year  = {2024},

date = {2024-07-23},

urldate = {2024-07-23},

abstract = {Aging is associated with a progressive decline in the capacity for physical activity. The objective of the current study was to evaluate the effect of an intermittent hyperbaric oxygen therapy (HBOT) protocol on maximal physical performance and cardiac perfusion in sedentary older adults.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Hyperbaric oxygen therapy: future prospects in regenerative therapy and anti-aging},

author = {Gupta M and Rathored J},

url = {https://europepmc.org/article/MED/38757145},

year  = {2024},

date = {2024-05-02},

abstract = {Hyperbaric Oxygen Therapy (HBOT) utilizes 100% oxygen at high atmospheric pressure for clinical applications. HBOT has proven to be an effective supplementary treatment for a variety of clinical and pathological disorders. HBOT's therapeutic results are based on the physiological effects of increased tissue oxygenation, or improved oxygen bioavailability. HBOT's current indications in illnesses like as wound healing, thermal or radiation burns, and tissue necrosis point to its function in facilitating the regeneration process. Various research has revealed that HBOT plays a function in vascularization, angiogenesis, and collagen production augmentation. Individual regeneration capacity is influenced by both environmental and genetic factors. Furthermore, the regenerating ability of different types of tissues varies, and this ability declines with age. HBOT affects physiological processes at the genetic level by altering gene expression, delaying cell senescence, and assisting in telomere length enhancement. The positive results in a variety of indications, ranging from tissue regeneration to better cognitive function, indicate that it has enormous potential in regenerative and anti-aging therapy.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Medical Ozone: A Redox Regulator with Selectivity for Rheumatoid Arthritis Patients},

author = {Olga Sonia León Fernández and Gabriel Takon Oru and Renate Viebahn-Haensler and Gilberto López Cabreja and Irainis Serrano Espinosa and María Elena Corrales Vázquez},

url = {https://europepmc.org/article/MED/38543177},

year  = {2024},

date = {2024-03-19},

abstract = {Rheumatoid arthritis (RA) and osteoarthritis (OA) are the most common arthritic diseases. Medical ozone has demonstrated its effectiveness in combination therapy with methotrexate or non-steroidal anti-inflammatory drugs for RA and OA, respectively. Although RA and OA have been compared from different points of view, few studies have considered their redox status in spite of the oxidative processes that are involved in both diseases. The aim of this study was to compare RA with OA, evaluating their redox status and the effects of ozone on their clinical response to combined therapy with ozone. The redox status of 80 patients was determined: antioxidant defenses, injury markers, two subjective variables (pain and disability), and levels of antibodies against cyclic citrullinated peptides were evaluated. Oxidative stress and clinical response to combined therapy with ozone was higher than in the case of RA. After medical ozone treatment, there was an increase in antioxidant defense and a decrease in injury markers as well as pain, disability, and autoantibody concentrations. Redox biomarkers were able to differentiate between both arthritic diseases and combined therapy with ozone (methotrexate + ozone), showing a therapeutic selectivity for RA in comparison with OA.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {How Ozone Applications in the Blood Can Influence Clinical Therapy Success via the Modulation of Cell Biology and Immunity},

author = {Salvatore Chirumbolo and Luigi Valdenassi and Umberto Tirelli and Giovanni Ricevuti and Sergio Pandolfi and Francesco Vaiano and Antonio Galoforo and Fortunato Loprete and Vincenzo Simonetti and Marianna Chierchia and Debora Bellardi and Tommaso Richelmi and Marianno Franzini},

url = {https://www.mdpi.com/2079-7737/12/12/1512},

year  = {2023},

date = {2023-12-11},

abstract = {Background. Ozone is an allotrope of oxygen whose use in medicine has rapidly grown in recent years. Ozonated blood allows for the use of ozone in a safe modality, as plasma and blood cells are endowed with an antioxidant system able to quench ozone’s pro-oxidant property and to elicit the Nrf2/Kwap1/ARE pathway. Methods. We present two clinical studies, a case-series (six patients) observational study adopting ozone as a major autohemotherapy and topical ozone to address infected post-surgical wounds with multi-drug resistant bacteria and an observational study (250 patients) using ozonated blood for treating knee osteoarthritis. Results. Ozonated blood via major autohemotherapy reduced the extent of infections in wounds, reduced the inflammatory biomarkers by more than 75% and improved patients’ QoL, whereas ozonated blood via minor autohemotherapy improved significantly (p < 0.001) WOMAC and Lequesne’s parameters in knee osteoarthritis. Conclusions. The models described, i.e., ozone autohemotherapy in wound antimicrobial treatment and ozonated blood in knee osteoarthrosis, following our protocols, share the outstanding ability of ozone to modulate the innate immune response and address bacterial clearance as well as inflammation and pain.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Cell-free therapy based on extracellular vesicles: a promising therapeutic strategy for peripheral nerve injury},

author = {Tianhao Yu and Yingxi Xu and Muhammad Arslan Ahmad and Rabia Javed and Haruo Hagiwara and Xiaohong Tian},

url = {https://stemcellres.biomedcentral.com/articles/10.1186/s13287-023-03467-5#:~:text=MSC%2Dderived%20exosomes%20have%20a,in%20the%20peripheral%20nerve%20microenvironment},

year  = {2023},

date = {2023-09-19},

abstract = {Peripheral nerve injury (PNI) is one of the public health concerns that can result in a loss of sensory or motor function in the areas in which injured and non-injured nerves come together. Up until now, there has been no optimized therapy for complete nerve regeneration after PNI. Exosome-based therapies are an emerging and effective therapeutic strategy for promoting nerve regeneration and functional recovery. Exosomes, as natural extracellular vesicles, contain bioactive molecules for intracellular communications and nervous tissue function, which could overcome the challenges of cell-based therapies. Furthermore, the bioactivity and ability of exosomes to deliver various types of agents, such as proteins and microRNA, have made exosomes a potential approach for neurotherapeutics. However, the type of cell origin, dosage, and targeted delivery of exosomes still pose challenges for the clinical translation of exosome therapeutics. In this review, we have focused on Schwann cell and mesenchymal stem cell (MSC)-derived exosomes in nerve tissue regeneration. Also, we expressed the current understanding of MSC-derived exosomes related to nerve regeneration and provided insights for developing a cell-free MSC therapeutic strategy for nerve injury.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Stem cell-based therapeutic strategies for rotator cuff tendinopathy},

author = {Zetao Wang and Youguo Liao and Canlong Wang and Chenqi Tang and Cailian Fang and Junchao Luo and Hengzhi Liu and Xianan Mo and Zicheng Wang and Lingfang Shen and Junjuan Wang and Xiao Chen and Jianyou Li and Weiliang Shen},

url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470406/},

year  = {2023},

date = {2023-07-23},

urldate = {2023-07-23},

abstract = {Rotator cuff tendinopathy is a common musculoskeletal disorder that imposes significant health and economic burden. Stem cell therapy has brought hope for tendon healing in patients with final stage rotator cuff tendinopathy. Some clinical trials have confirmed the effectiveness of stem cell therapy for rotator cuff tendinopathy, but its application has not been promoted and approved. There are still many issues that should be solved prior to using stem cell therapy in clinical applications. The optimal source and dose of stem cells for rotator cuff tendinopathy should be determined. We also proposed novel prospective approaches that can overcome cell population heterogeneity and standardize patient types for stem cell applications.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Exploring the Potential of Stem Cell-Based Therapy for Aesthetic and Plastic Surgery},

author = {Dang-Khoa Tran and Thuy Nguyen and Thi Phuong and Nhat-Le Bui and Vijai Singh and Qi Hao Looi},

url = {https://doi.org/10.1109/RBME.2021.3134994},

doi = {https://doi.org/10.1109/RBME.2021.3134994},

year  = {2023},

date = {2023-01-05},

urldate = {2023-01-05},

abstract = {Over the last decade, stem cell-associated therapies are widely used because of their potential in self-renewable and multipotent differentiation ability. Stem cells have become more attractive for aesthetic uses and plastic surgery, including scar reduction, breast augmentation, facial contouring, hand rejuvenation, and anti-aging. The current preclinical and clinical studies of stem cells on aesthetic uses also showed promising outcomes. Adipose-derived stem cells are commonly used for fat grafting that demonstrated scar improvement, anti-aging, skin rejuvenation properties, etc. While stem cell-based products have yet to receive approval from the FDA for aesthetic medicine and plastic surgery. Moving forward, the review on the efficacy and potential of stem cell-based therapy for aesthetic and plastic surgery is limited. In the present review, we discuss the current status and recent advances of using stem cells for aesthetic and plastic surgery. The potential of cell-free therapy and tissue engineering in this field is also highlighted. The clinical applications, advantages, and limitations are also discussed. This review also provides further works that need to be investigated to widely apply stem cells in the clinic, especially in aesthetic and plastic contexts.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Stem Cells in Clinical Trials on Neurological Disorders: Trends in Stem Cells Origins, Indications, and Status of the Clinical Trials.},

author = {Eugenia D Namiot and Jenni Viivi Linnea Niemi and Vladimir N Chubarev and Vadim V Tarasov and Helgi B Schiöth},

year  = {2022},

date = {2022-09-28},

urldate = {2022-09-28},

abstract = {Neurological diseases can significantly reduce the quality and duration of life. Stem cells provide a promising solution, not only due to their regenerative features but also for a variety of other functions, including reducing inflammation and promoting angiogenesis. Although only hematopoietic cells have been approved by the FDA so far, the number of trials continues to expand. We analyzed 492 clinical trials and illustrate the trends in stem cells origins, indications, and phase and status of the clinical trials. The most common neurological disorders treated with stem cells were injuries of brain, spinal cord, and peripheral nerves (14%), stroke (13%), multiple sclerosis (12%), and brain tumors (11%). Mesenchymal stem cells dominated (83%) although the choice of stem cells was highly dependent on the neurological disorder. Of the 492 trials, only two trials have reached phase 4, with most of all other trials being in phases 1 or 2, or transitioning between them (83%). Based on a comparison of the obtained results with similar works and further analysis of the literature, we discuss some of the challenges and future directions of stem cell therapies in the treatment of neurological diseases.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Interaction between Mesenchymal Stem Cells and the Immune System in Rheumatoid Arthritis},

author = {Darina Bačenkov and Marianna Trebuňová and Radoslav Morochovič and Erik Dosedla and Alena Findrik Balogová},

url = {https://doi.org/10.3390%2Fph15080941},

year  = {2022},

date = {2022-08-15},

abstract = {Rheumatoid arthritis (RA) is an autoimmune disease that causes damage to joints. This review focuses on the possibility of influencing the disease through immunomodulation by mesenchymal stem cells (MSCs). There is an occurrence of rheumatoid factor and RA-specific autoantibodies to citrullinated proteins in most patients. Citrulline proteins have been identified in the joints of RA patients, and are considered to be the most suitable candidates for the stimulation of anti-citrulline protein antibodies production. Fibroblast-like proliferating active synoviocytes actively promote inflammation and destruction in the RA joint, in association with pro-inflammatory cells. The inflammatory process may be suppressed by MSCs, which are a population of adherent cells with the following characteristic phenotype: CD105+, CD73+, CD90+, CD45−, CD34− and HLA DR−. Following the stimulation process, MSCs are capable of immunomodulatory action through the release of bioactive molecules, as well as direct contact with the cells of the immune system. Furthermore, MSCs show the ability to suppress natural killer cell activation and dendritic cells maturation, inhibit T cell proliferation and function, and induce T regulatory cell formation. MSCs produce factors that suppress inflammatory processes, such as PGE2, TGF-β, HLA-G5, IDO, and IL-10. These properties suggest that MSCs may affect and suppress the excessive inflammation that occurs in RA. The effect of MSCs on rheumatoid arthritis has been proven to be a suitable alternative treatment thanks to successful experiments and clinical studies.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Exosomes and exosomal miRNAs: A new therapy for intervertebral disc degeneration},

author = {Zhichao Li and Yan Wu and Guoqing Tan and Zhanwang Xu and Haipeng Xue},

year  = {2022},

date = {2022-08-09},

abstract = {Low back pain has been found as a major cause of global disease burden and disability. Intervertebral disc degeneration is recognized as the vital factor causing low back pain. Intervertebral disc degeneration has a complex mechanism and cannot be avoided. Traditional strategies for the treatment of intervertebral disc degeneration cannot meet the needs of intervertebral disc regeneration, so novel treatment methods are urgently required. Exosomes refer to extracellular vesicles that can be released by most cells, and play major roles in intercellular material transport and information transmission. MicroRNAs have been identified as essential components in exosomes, which can be selectively ingested by exosomes and delivered to receptor cells for the regulation of the physiological activities and functions of receptor cells. Existing studies have progressively focused on the role of exosomes and exosomal microRNAs in the treatment of intervertebral disc degeneration. The focus on this paper is placed on the changes of microenvironment during intervertebral disc degeneration and the biogenesis and mechanism of action of exosomes and exosomal microRNAs. The research results and deficiencies of exosomes and exosomal microRNAs in the regulation of apoptosis, extracellular matrix homeostasis, inflammatory response, oxidative stress, and angiogenesis in intervertebral disc degeneration are primarily investigated. The aim of this paper is to identify the latest research results, potential applications and challenges of this emerging treatment strategy.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {The biology, function, and biomedical applications of exosomes},

author = {Zhaoxia Zhang and Tao Mi and Liming Jin and Mujie Li and Chenghao Zhanghuang and Jinkui Wang and Xiaojun Tan and Hongxu Lu and Lianju Shen and Chunlan Long and Guanghui Weiand Dawei Hecorresponding},

url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284776/},

year  = {2022},

date = {2022-07-15},

abstract = {Exosomes derived from mesenchymal stem cells (MSCs) have shown to have effective application prospects in the medical field, but exosome yield is very low. The production of exosome mimetic vesicles (EMVs) by continuous cell extrusion leads to more EMVs than exosomes, but whether the protein compositions of MSC-derived EMVs (MSC-EMVs) and exosomes (MSC-exosomes) are substantially different remains unknown. The purpose of this study was to conduct a comprehensive proteomic analysis of MSC-EMVs and MSC-exosomes and to simply explore the effects of exosomes and EMVs on wound healing ability. This study provides a theoretical basis for the application of EMVs and exosomes.



In this study, EMVs from human umbilical cord MSCs (hUC MSCs) were isolated by continuous extrusion, and exosomes were identified after hUC MSC ultracentrifugation. A proteomic analysis was performed, and 2315 proteins were identified. The effects of EMVs and exosomes on the proliferation, migration and angiogenesis of human umbilical vein endothelial cells (HUVECs) were evaluated by cell counting kit-8, scratch wound, transwell and tubule formation assays. A mouse mode was used to evaluate the effects of EMVs and exosomes on wound healing.



Bioinformatics analyses revealed that 1669 proteins in both hUC MSC-EMVs and hUC MSC-exosomes play roles in retrograde vesicle-mediated transport and vesicle budding from the membrane. The 382 proteins unique to exosomes participate in extracellular matrix organization and extracellular structural organization, and the 264 proteins unique to EMVs target the cell membrane. EMVs and exosomes can promote wound healing and angiogenesis in mice and promote the proliferation, migration and angiogenesis of HUVECs.



This study presents a comprehensive proteomic analysis of hUC MSC-derived exosomes and EMVs generated by different methods. The tissue repair function of EMVs and exosomes was herein verified by wound healing experiments, and these results reveal their potential applications in different fields based on analyses of their shared and unique proteins.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Mesenchymal Stem Cell-Derived Exosomes and Intervertebral Disc Regeneration Review},

author = {Bhujel B and Shin HE and Choi DJ and Han I},

url = {https://europepmc.org/article/MED/35806304},

doi = {https://europepmc.org/article/MED/35806304},

year  = {2022},

date = {2022-06-30},

urldate = {2022-06-30},

abstract = {Intervertebral disc degeneration (IVDD) is a common cause of lower back pain (LBP), which burdens individuals and society as a whole. IVDD occurs as a result of aging, mechanical trauma, lifestyle factors, and certain genetic abnormalities, leads to loss of nucleus pulposus, alteration in the composition of the extracellular matrix, excessive oxidative stress, and inflammation in the intervertebral disc. Pharmacological and surgical interventions are considered a boon for the treatment of IVDD, but the effectiveness of those strategies is limited. Mesenchymal stem cells (MSCs) have recently emerged as a possible promising regenerative therapy for IVDD due to their paracrine effect, restoration of the degenerated cells, and capacity for differentiation into disc cells. Recent investigations have shown that the pleiotropic effect of MSCs is not related to differentiation capacity but is mediated by the secretion of soluble paracrine factors. Early studies have demonstrated that MSC-derived exosomes have therapeutic potential for treating IVDD by promoting cell proliferation, tissue regeneration, modulation of the inflammatory response, and reduced apoptosis. This paper highlights the current state of MSC-derived exosomes in the field of treatment of IVDD with further possible future developments, applications, and challenges.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Advances in Stem Cell Therapies for Rotator Cuff Injuries},

author = {Hao-Nan Wang and Xiao Rong and Lu-Ming Yang and Wei-Zhong Hua and Guo-Xin Nicorresponding},

url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174670/},

year  = {2022},

date = {2022-05-25},

abstract = {Rotator cuff injury is a common upper extremity musculoskeletal disease that may lead to persistent pain and functional impairment. Despite the clinical outcomes of the surgical procedures being satisfactory, the repair of the rotator cuff remains problematic, such as through failure of healing, adhesion formation, and fatty infiltration. Stem cells have high proliferation, strong paracrine action, and multiple differentiation potential, which promote tendon remodeling and fibrocartilage formation and increase biomechanical strength. Additionally, stem cell-derived extracellular vesicles (EVs) can increase collagen synthesis and inhibit inflammation and adhesion formation by carrying regulatory proteins and microRNAs. Therefore, stem cell-based therapy is a promising therapeutic strategy that has great potential for rotator cuff healing. In this review, we summarize the advances of stem cells and stem cell-derived EVs in rotator cuff repair and highlight the underlying mechanism of stem cells and stem cell-derived EVs and biomaterial delivery systems. Future studies need to explore stem cell therapy in combination with cellular factors, gene therapy, and novel biomaterial delivery systems.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Mesenchymal Stem Cells From Different Sources in Meniscus Repair and Regeneration},

author = {Guocheng Ding and Jianing Du and Xiaoqing Hu and Yingfang},

url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091333/},

year  = {2022},

date = {2022-04-27},

urldate = {2022-04-27},

abstract = {Meniscus damage is a common trauma that often arises from sports injuries or menisci tissue degeneration. Current treatment methods focus on the repair, replacement, and regeneration of the meniscus to restore its original function. The advance of tissue engineering provides a novel approach to restore the unique structure of the meniscus. Recently, mesenchymal stem cells found in tissues including bone marrow, peripheral blood, fat, and articular cavity synovium have shown specific advantages in meniscus repair. Although various studies explore the use of stem cells in repairing meniscal injuries from different sources and demonstrate their potential for chondrogenic differentiation, their meniscal cartilage-forming properties are yet to be systematically compared. Therefore, this review aims to summarize and compare different sources of mesenchymal stem cells for meniscal repair and regeneration.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Efficacy and Safety of Mesenchymal Stem Cell in the Treatment of Autoimmune Disease},

author = {Liuting Zeng and Ganpeng Yu and Kailin Yang and Wang Xiang and Jun Li and Hua Chen},

doi = {https://doi.org/10.1155%2F2022%2F9463314},

year  = {2022},

date = {2022-03-24},

abstract = {Autoimmune diseases are a series of diseases caused by the immune system's response to self-antigens, resulting in self-tissue damage or dysfunction. It mainly includes systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome, polymyositis and dermatomyositis. Many autoimmune diseases are characterized by the production of autoantibodies, which bind to the host's own proteins or form immune complexes and deposit in tissues. Any organ of the body may become a target organ for autoimmunity, including skin, joints, kidneys, and blood vessels. The inflammatory effect caused by autoantibodies is mediated by binding to Fc receptors on leukocytes, which is an important cause of downstream tissue damage. Meanwhile, autoantibodies can also directly mediate tissue damage in diseases through complement activation [5]. In the development stage of the disease, genetic factors and environmental factors may interact in turn to promote the development of autoimmunity and ultimately lead to tissue inflammation and damage, becoming a chronic disease with multiple organs and multiple system damage.



Clinically, once diagnosed, patients should be treated with medication in time to avoid further development of the disease causing damage to organs or systems such as the liver and kidney. Clinically, commonly used glucocorticoids and traditional disease-improving antirheumatic drugs (DMARDs) have good anti-inflammatory, pain-relieving, and improving or delaying disease progression effects and are still used as the first-line choice for clinical treatment of rheumatic immune diseases [9, 10]. However, for first-line treatments with single or combined regimens that do not respond well or cannot tolerate them, other treatment options with potential curative effects need to be considered . For example, stem cell transplantation, biological preparations, or new botanical preparations, as well as some antirheumatic drug candidates that may modulate or suppress immunity, in order to alleviate the condition of patients with refractory rheumatism and improve their quality of life. Among them, mesenchymal stem cells are one of the most promising therapeutic strategies },

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Therapeutic Effects of Physical Exercise and the Mesenchymal Stem Cell Secretome by Modulating Neuroinflammatory Response in Multiple Sclerosis},

author = {Lina María González and Laura Natalia Ospina and Laura Elena Sperling and Orlando Chaparro and Jaison Daniel Cucarián},

url = {https://www.eurekaselect.com/article/119324},

year  = {2022},

date = {2022-02-18},

urldate = {2022-02-18},

abstract = {Multiple Sclerosis (MS) is a neurodegenerative, demyelinating, and chronic inflammatory disease characterized by Central Nervous System (CNS) lesions that lead to high levels of disability and severe physical and cognitive disturbances. Conventional therapies are not enough to control the neuroinflammatory process in MS and are not able to inhibit ongoing damage to the CNS. Thus, the secretome of mesenchymal stem cells (MSC-S) has been postulated as a potential therapy that could mitigate symptoms and disease progression. We considered that its combination with physical exercise (EX) could induce superior effects and increase the MSC-S effectiveness in this condition. Recent studies have revealed that both EX and MSC-S share similar mechanisms of action that mitigate auto-reactive T cell infiltration, regulate the local inflammatory response, modulate the proinflammatory profile of glial cells, and reduce neuronal damage. Clinical and experimental studies have reported that these treatments in an isolated way also improve myelination, regeneration, promote the release of neurotrophic factors, and increase the recruitment of endogenous stem cells. Together, these effects reduce disease progression and improve patient functionality. Despite these results, the combination of these methods has not yet been studied in MS. In this review, we focus on molecular elements and cellular responses induced by these treatments in a separate way, showing their beneficial effects in the control of symptoms and disease progression in MS, as well as indicating their contribution in clinical fields. In addition, we propose the combined use of EX and MSC-S as a strategy to boost their reparative and immunomodulatory effects in this condition, combining their benefits on synaptogenesis, neurogenesis, remyelination, and neuroinflammatory response. The findings here reported are based on the scientific evidence and our professional experience that will bring significant progress to regenerative medicine to deal with this condition.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Stem cell therapy for COVID-19 pneumonia},

author = {Maziar Malekzadeh Kebria and Peiman Brouki Milan and Noshad Peyravian and Jafar Kiani and Soheil Khatibi and Masoud Mozafari},

url = {https://link.springer.com/article/10.1186/s43556-021-00067-8},

year  = {2022},

date = {2022-02-17},

urldate = {2022-02-17},

abstract = {Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is a highly contagious microorganism, and despite substantial investigation, no progress has been achieved in treating post-COVID complications. However, the virus has made various mutations and has spread around the world. Researchers have tried different treatments to reduce the side effects of the COVID-19 symptoms. One of the most common and effective treatments now used is steroid therapy to reduce the complications of this disease. Long-term steroid therapy for chronic inflammation following COVID-19 is harmful and increases the risk of secondary infection, and effective treatment remains challenging owing to fibrosis and severe inflammation and infection. Sometimes our immune system can severely damage ourselves in disease. In the past, many researchers have conducted various studies on the immunomodulatory properties of stem cells. This property of stem cells led them to modulate the immune system of autoimmune diseases like diabetes, multiple sclerosis, and Parkinson's. Because of their immunomodulatory properties, stem cell-based therapy employing mesenchymal or hematopoietic stem cells may be a viable alternative treatment option in some patients. By priming the immune system and providing cytokines, chemokines, and growth factors, stem cells can be employed to build a long-term regenerative and protective response. This review addresses the latest trends and rapid progress in stem cell treatment for Acute Respiratory Distress Syndrome (ARDS) following COVID-19.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Mesenchymal Stem Cell-Derived Exosomes as a Novel Strategy for the Treatment of Intervertebral Disc Degeneration},

author = {Lin Lu and Aoshuang Xu and Fei Gao and Chenjun Tian and Honglin Wang and Jiayao Zhang and Yi Xie and Pengran Liu and Songxiang Liu and Cao Yang and Zhewei Ye and Xinghuo Wu},

doi = {https://europepmc.org/article/MED/35141231},

year  = {2022},

date = {2022-01-24},

abstract = {Intervertebral disc degeneration (IVDD) has been reported to be the most prevalent contributor to low back pain, posing a significant strain on the healthcare systems on a global scale. Currently, there are no approved therapies available for the prevention of the progressive degeneration of intervertebral disc (IVD); however, emerging regenerative strategies that aim to restore the normal structure of the disc have been fundamentally promising. In the last decade, mesenchymal stem cells (MSCs) have received a significant deal of interest for the treatment of IVDD due to their differentiation potential, immunoregulatory capabilities, and capability to be cultured and regulated in a favorable environment. Recent investigations show that the pleiotropic impacts of MSCs are regulated by the production of soluble paracrine factors. Exosomes play an important role in regulating such effects. In this review, we have summarized the current treatments for disc degenerative diseases and their limitations and highlighted the therapeutic role and its underlying mechanism of MSC-derived exosomes in IVDD, as well as the possible future developments for exosomes.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Human mesenchymal stem cells treatment for severe COVID-19},

author = {Lei Shi and Xin Yuan and Weiqi Yao and Siyu Wang and Chao Zhang and Bo Zhang and Jinwen Song and Lei Huang and Zhe Xu},

url = {https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00583-1/fulltext},

year  = {2021},

date = {2021-12-25},

abstract = {The long-term consequences of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study assessed the 1-year outcomes in patients with severe COVID-19, who were recruited in our previous UC-MSC clinical trial.

Methods



In this prospective, longitudinal, cohort study, 100 patients enrolled in our phase 2 trial were prospectively followed up at 3-month intervals for 1 year to evaluate the long-term safety and effectiveness of UC-MSC treatment. The primary endpoint was an altered proportion of whole-lung lesion volumes measured by high-resolution CT. Other imaging outcomes, 6 min walking distance (6-MWD), lung function, plasma biomarkers, and adverse events were also recorded and analyzed. This trial was registered with ClinicalTrials.gov (NCT04288102).

Findings



MSC administration improved in whole-lung lesion volume compared with the placebo with a difference of −10.8% (95% CI: −20.7%, −1.5%, p = 0.030) on day 10. MSC also reduced the proportion of solid component lesion volume compared with the placebo at each follow-up point. More interestingly, 17.9% (10/56) of patients in the MSC group had normal CT images at month 12, but none in the placebo group (p = 0.013). The incidence of symptoms was lower in the MSC group than in the placebo group at each follow-up time. Neutralizing antibodies were all positive, with a similar median inhibition rate (61.6% vs. 67.6%) in both groups at month 12. No difference in adverse events at the 1-year follow-up and tumor markers at month 12 were observed between the two groups.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Hyperbaric oxygen therapy induces transcriptome changes in elderly: a prospective trial.},

author = {Hadanny A and Forer R and Volodarsky D and Daniel-Kotovsky M and Catalogna M and Zemel Y and Bechor Y and and Efrati S.},

url = {https://europepmc.org/article/MED/34818212},

year  = {2021},

date = {2021-11-24},

abstract = {Aging is characterized by the progressive loss of physiological capacity. Changes in gene expression can alter activity in defined age-related molecular pathways leading to cellular aging and increased aging disease susceptibility. The aim of the current study was to evaluate whether hyperbaric oxygen therapy (HBOT) affects gene expression in normal, non-pathological, aging adults.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}